Exploring mTOR inhibition as treatment for mitochondrial disease

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Leigh syndrome and MELAS are severe pediatric mitochondrial diseases with no effective treatments.
• The mammalian target of rapamycin (mTOR) pathway is implicated in mitochondrial disease progression.

Observation:

• mTOR inhibition showed promise in preclinical models of Leigh syndrome.
• Two children, one with Leigh syndrome and one with MELAS, were treated with everolimus, an mTOR inhibitor.

Findings:

• The child with Leigh syndrome experienced sustained clinical benefit from everolimus treatment.
• The child with MELAS did not respond to everolimus and succumbed to progressive disease.

Implications:

• mTOR inhibition may be a viable therapeutic strategy for Leigh syndrome.
• Differential responses to mTOR inhibition highlight the need for personalized treatment approaches in mitochondrial diseases.